A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery

Gary J. Weil, Julie A. Jacobson, Jonathan D. King

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.

Original languageEnglish
Pages (from-to)S60-S64
JournalInternational Health
Volume13
DOIs
StatePublished - Jan 1 2021

Keywords

  • elimination
  • ivermectin
  • lymphatic filariasis
  • mass drug administration
  • therapy

Fingerprint

Dive into the research topics of 'A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery'. Together they form a unique fingerprint.

Cite this